Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489748 | 0.94 | KDM5A (0.54) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18489731 | 0.89 | ROCK2 (0.46) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18526200 | 0.88 | KDM5A (0.54) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18526154 | 0.88 | PIM1 (0.48) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18526075 | 0.88 | ROCK2 (0.48) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18526199 | 0.87 | GCGR (0.48) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18526134 | 0.87 | KDM5A (0.44) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18489712 | 0.87 | SCD (0.48) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18489775 | 0.87 | KDM5A (0.46) | KDM5AKDM4CKDM5BSCDROCK2 | |
| SCHEMBL18526077 | 0.87 | ROCK2 (0.49) | KDM5AKDM4CKDM5BSCDROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | KDM5A 1424/4885KDM4C 2216/4885KDM5B 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.